Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALOP: Octreotide vs Splenic Artery Ligation in LDLT
NCT06974344Phase 4Not yet recruiting
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- Jun 2025
- Primary completion
- May 2030
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Octreotide long-acting injection in small-for-size syndrome (SFSS) (2 arms), sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoints: Comprehensive Complication Index at 90 days, Small-for-Size Syndrome Rate at 14 days and 3 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
Octreotide long-acting injection
03
Conditions
small-for-size syndrome (SFSS)
Beyond the preview
Go deeper on NCT06974344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974344.